Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) Enterprise Value: 2021-2025

Historic Enterprise Value for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $4.4 billion.

  • Krystal Biotech's Enterprise Value fell 5.67% to $4.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year decrease of 17.58%. This contributed to the annual value of $3.9 billion for FY2024, which is 0.04% down from last year.
  • Krystal Biotech's Enterprise Value amounted to $4.4 billion in Q3 2025, which was up 33.06% from $3.3 billion recorded in Q2 2025.
  • Over the past 5 years, Krystal Biotech's Enterprise Value peaked at $4.7 billion during Q2 2024, and registered a low of $816.3 million during Q3 2021.
  • In the last 3 years, Krystal Biotech's Enterprise Value had a median value of $3.9 billion in 2023 and averaged $3.7 billion.
  • As far as peak fluctuations go, Krystal Biotech's Enterprise Value surged by 162.57% in 2024, and later dropped by 29.76% in 2025.
  • Krystal Biotech's Enterprise Value (Quarterly) stood at $1.1 billion in 2021, then surged by 48.60% to $1.7 billion in 2022, then spiked by 135.45% to $3.9 billion in 2023, then dropped by 0.04% to $3.9 billion in 2024, then declined by 5.67% to $4.4 billion in 2025.
  • Its last three reported values are $4.4 billion in Q3 2025, $3.3 billion for Q2 2025, and $4.6 billion during Q1 2025.